This webinar is being recorded.

**Q&A Webinar**

June 25, 2020 @ 3 PM EDT

Please submit your questions in the “Q&A” box (specific questions about scientific fit will not be addressed)

https://commonfund.nih.gov/newinnovator
Panelists

Ravi Basavappa, Ph.D.
Program Leader
Office of the Director

Eugene Carstea, Ph.D.
Branch Chief
Center for Scientific Review

Becky Miller, Ph.D.
Program Officer
Office of the Director

Ellie Murcia, M.Ed.
Program Specialist
Office of the Director
The Common Fund (in the NIH Office of the Director)

**Current Programs:**

- **Data/Tools/Methods**
  - Big Data to Knowledge (BD2K)
  - Gabriella Miller Kids First
  - Genotype-Tissue Expression (GTEx)
  - Glycoscience
  - Human BioMolecular Atlas Program (HuBMAP)
  - Illuminating the Druggable Genome (IDG)
  - Knockout Mouse Phenotyping (KOMP)
  - Library of Integrated Network-Based Cellular Signatures (LINCS)
  - Metabolomics
  - Regenerative Medicine Program (RMP)
  - Science of Behavior Change (SOBS)
  - Somatic Cell Genome Editing (SCGE)
  - Stimulating Peripheral Activity to Relieve Conditions (SPARC)
  - Transformative High Resolution Cryo-Electron Microscopy (CryoEM)

- **New Paradigms**
  - 4D Nucleome (4DN)
  - Extracellular RNA Communication (exRNA)
  - Molecular Transducers of Physical Activity Consortium (MoTrPAC)

- **New Types of Clinical Partnerships**
  - Acute to Chronic Pain Signatures (A2CPS)
  - Global Health
  - HCS Research Collaboratory
  - Undiagnosed Diseases Network (UDN)

- **Transformative Workforce Support**
  - Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
  - High-Risk, High-Reward Research Program
    - Pioneer Award
    - New Innovator Award
    - Transformative Research Award
    - Early Independence Award
  - Strengthening the Biomedical Research Workforce (BEST)
The Common Fund (in the NIH Office of the Director)

Current Programs:

**Data/Tools/Methods**
- Big Data to Knowledge (BD2K)
- Gabriella Miller Kids First
- Genotype-Tissue Expression (GTEx)
- Glycoscience
- Human BioMolecular Atlas Program (HuBMAP)
- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)
- Metabolomics
- Regenerative Medicine Program (RMP)
- Science of Behavior Change (SOBS)
- Somatic Cell Genome Editing (SCGE)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)

**New Paradigms**
- 4D Nucleome (4DN)
- Extracellular RNA Communication (exRNA)
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)

**New Types of Clinical Partnerships**
- Acute to Chronic Pain Signatures (A2CPS)
- Global Health
- HCS Research Collaboratory
- Undiagnosed Diseases Network (UDN)

**Transformative Workforce Support**
- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- High-Risk, High-Reward Research Program
  - Pioneer Award
  - New Innovator Award
  - Transformative Research Award
  - Early Independence Award
- Strengthening the Biomedical Research Workforce (BEST)

*CF programs may be useful for your research: FOAs, access to high-end instruments, databases, reagents, protocols, ....*
The Common Fund (in the NIH Office of the Director)  
Current Programs:  

Data/Tools/Methods  
- Big Data to Knowledge (BD2K)  
- Gabriella Miller Kids First  
- Genotype-Tissue Expression (GTEx)  
- Glycoscience  
- Human BioMolecular Atlas Program (HuBMAP)  
- Illuminating the Druggable Genome (IDG)  
- Knockout Mouse Phenotyping (KOMP)  
- Library of Integrated Network-Based Cellular Signatures (LINCS)  
- Metabolomics  
- Regenerative Medicine Program (RMP)  
- Science of Behavior Change (SOBS)  
- Somatic Cell Genome Editing (SCGE)  
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)  
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)  

New Paradigms  
- 4D Nucleome (4DN)  
- Extracellular RNA Communication (exRNA)  
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)  

New Types of Clinical Partnerships  
- Acute to Chronic Pain Signatures (A2CPS)  
- Global Health  
- HCS Research Collaboratory  
- Undiagnosed Diseases Network (UDN)  

Transformative Workforce Support  
- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)  
- High-Risk, High-Reward Research Program  
  - Pioneer Award  
  - New Innovator Award  
  - Transformative Research Award  
  - Early Independence Award  
- Strengthening the Biomedical Research Workforce (BEST)  

commonfund.nih.gov
High-Risk, High-Reward Research Program

Annual funding opportunities
High-Risk, High-Reward Research Program

High-risk, high-impact ideas
High-Risk, High-Reward Research Program

No preliminary data or detailed experimental plan required
Any topic relevant to NIH mission
Any topic relevant to NIH mission, including: behavioral, social, biomedical, applied, and formal sciences, and basic, translational, or clinical research
High-Risk, High-Reward Research Program

Encourages applications from investigators with diverse backgrounds and from the full spectrum of eligible institutions
<table>
<thead>
<tr>
<th>Chair</th>
<th>James M. Anderson, MD, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Leader</td>
<td>Ravi Basavappa, PhD</td>
</tr>
<tr>
<td></td>
<td>OSC/DPCPSI/OD</td>
</tr>
<tr>
<td>Members</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kristin Abraham, PhD</td>
</tr>
<tr>
<td></td>
<td>NIDDK</td>
</tr>
<tr>
<td></td>
<td>Vernon Anderson, PhD</td>
</tr>
<tr>
<td></td>
<td>NIGMS</td>
</tr>
<tr>
<td></td>
<td>Hugh Auchincloss, MD</td>
</tr>
<tr>
<td></td>
<td>NIAID</td>
</tr>
<tr>
<td></td>
<td>David Balshaw, PhD</td>
</tr>
<tr>
<td></td>
<td>NIEHS</td>
</tr>
<tr>
<td>Abraham P. Bautista, PhD</td>
<td>NIAAA</td>
</tr>
<tr>
<td>Eugene Carstea, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>Robert H Carter, MD</td>
<td>NIAMS</td>
</tr>
<tr>
<td>Jennifer Collins, MR</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Christine Colvis, PhD</td>
<td>NCATS</td>
</tr>
<tr>
<td>Judith A. Cooper, PhD</td>
<td>NIDCD</td>
</tr>
<tr>
<td>Milton Corn, MD, FACP, FACMI</td>
<td>NLM</td>
</tr>
<tr>
<td>Cindy D. Davis, PhD</td>
<td>Office of Dietary Supplements/DPCPSI/OD</td>
</tr>
<tr>
<td>Emmeline Edwards, PhD</td>
<td>NCCIH</td>
</tr>
<tr>
<td>Zeynep Erim, PhD</td>
<td>NIBIB</td>
</tr>
<tr>
<td>Rene Etcheberrigaray, MD</td>
<td>NIA</td>
</tr>
<tr>
<td>Valerie Florance, PhD</td>
<td>NLM</td>
</tr>
<tr>
<td>Gabriel Hidalgo</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Christine Hunter, PhD, ABPP</td>
<td>OBSSSR/DPCPSI/OD</td>
</tr>
<tr>
<td>Raymond Jacobson, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>Flora Katz, PhD</td>
<td>FIC</td>
</tr>
<tr>
<td>Karen Kellton</td>
<td>OSC/DPCPSI/OD</td>
</tr>
<tr>
<td>Anthony Kirilusha, PhD</td>
<td>NIAMS</td>
</tr>
<tr>
<td>Susan Koester, PhD</td>
<td>NIMH</td>
</tr>
<tr>
<td>Rajiv Kumar, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>James Li, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>Roger Little, PhD</td>
<td>NIDA</td>
</tr>
<tr>
<td>James Mack, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>Judy A. Mietz, PhD</td>
<td>NCI</td>
</tr>
<tr>
<td>Becky Miller, PhD</td>
<td>OSC/DPCPSI/OD</td>
</tr>
<tr>
<td>Brett Miller, PhD</td>
<td>NICHD</td>
</tr>
<tr>
<td>Daniel Miller, PhD</td>
<td>NINDS</td>
</tr>
<tr>
<td>Michael Morse</td>
<td>OSC/DPCPSI/OD</td>
</tr>
<tr>
<td>Ellie Murcia, MEd</td>
<td>OSC/DPCPSI/OD</td>
</tr>
<tr>
<td>Srikanth Ranganathan, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>Diana (Dede) Rutberg, MBA</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Suzanne Ryan, PhD</td>
<td>CSR</td>
</tr>
<tr>
<td>John Satterlee, PhD</td>
<td>NIDA</td>
</tr>
<tr>
<td>Carol Shreffler, PhD</td>
<td>NIEHS</td>
</tr>
<tr>
<td>Lillian Shum, PhD</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Darren Sledjeski, PhD</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Heidi J. Sofia, PhD</td>
<td>NHGRI</td>
</tr>
<tr>
<td>Michael A. Steinmetz, PhD</td>
<td>NEI</td>
</tr>
<tr>
<td>Nathaniel Stinson, Jr., PhD, MD</td>
<td>NIMHD</td>
</tr>
<tr>
<td>Edmund Talley, PhD</td>
<td>NINDS</td>
</tr>
<tr>
<td>Stephanie Johnson Webb, PhD</td>
<td>NHLBI</td>
</tr>
<tr>
<td>Tasmeen Weik, DrPH, MPH</td>
<td>CSR</td>
</tr>
<tr>
<td>Elizabeth L. Wilder, PhD</td>
<td>OSC/DPCPSI/OD</td>
</tr>
</tbody>
</table>

commonfund.nih.gov
High-Risk, High-Reward Research Program

Supports unusually creative early career investigators proposing innovative, high-impact research

- Started in 2007
- Early Stage Investigator (no substantial NIH grant and within 10 years of doctoral degree or clinical training)
- Commit 25% research effort
- Awards of $1.5 million disbursed in first year of 5 year project period
- Uses DP2 activity code
# New Innovator Award - application

Follow instructions in SF424 application guide unless specific guidance is provided in the FOA

<table>
<thead>
<tr>
<th>Component</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific Aims Page</td>
<td>Do not use</td>
</tr>
<tr>
<td>Research Strategy Essay</td>
<td>10 pages (primary component of the application; see later slide for more information)</td>
</tr>
<tr>
<td>Biosketch</td>
<td>Only PI’s biosketch allowed</td>
</tr>
<tr>
<td>Bibliography &amp; References Cited</td>
<td>Do not use; include essential in references in Essay and within 10 page limit</td>
</tr>
<tr>
<td>Budget</td>
<td>No detailed budget allowed (indicate only $1.5M)</td>
</tr>
<tr>
<td>Equipment</td>
<td>Do not use</td>
</tr>
<tr>
<td>Letters of support</td>
<td>Do not use</td>
</tr>
<tr>
<td>Resource Sharing Plan</td>
<td>Do not use; will be requested as Just-in-Time information</td>
</tr>
<tr>
<td>Other components/forms</td>
<td>Use when appropriate, such as Authentication of Key Biol./Chem. Resources; Vertebrate Animals; Human Subjects; Biohazards</td>
</tr>
</tbody>
</table>
New Innovator Award - application

Follow instructions in SF424 application guide unless specific guidance is provided in the FOA

<table>
<thead>
<tr>
<th>Component</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific Aims Page</td>
<td>Do not use</td>
</tr>
<tr>
<td>Research Strategy Essay</td>
<td>10 pages (primary component of the application; see later slide for more information)</td>
</tr>
<tr>
<td>Biosketch</td>
<td>Only PI’s biosketch allowed</td>
</tr>
<tr>
<td>Bibliography &amp; References Cited</td>
<td>Do not use; include essential in references in Essay and within 10 page-limit</td>
</tr>
<tr>
<td>Budget</td>
<td>No detailed budget allowed (indicate only $1.5M)</td>
</tr>
<tr>
<td>Equipment</td>
<td>Do not use</td>
</tr>
<tr>
<td>Letters of support</td>
<td>Do not use</td>
</tr>
<tr>
<td>Resource Sharing Plan</td>
<td>Do not use; will be requested as Just-in-Time information</td>
</tr>
<tr>
<td>Other components/forms</td>
<td>Use when appropriate, such as Authentication of Key Biol./Chem. Resources; Vertebrate Animals; Human Subjects; Biohazards</td>
</tr>
</tbody>
</table>

commonfund.nih.gov
In 10 pages, use the following headings or subsections:

- **Project science areas** – 1 digit code and abbreviation for primary and secondary areas
- **Project Description** – Describe scientific importance of topic; overall approach to be taken; preliminary data not required, but accepted; state that to comply with the FOA, a detailed experimental plan and extensive are not being provided; however, provide sufficient evidence that proposal has been deeply considered and will be pursued in a robust and rigorous manner
- **Innovativeness** – Provide argument of why proposal is exceptionally innovative
- **Innovativeness** – Provide argument of why proposal is exceptionally innovative
- **Investigator qualifications** – Support your claim of innovativeness in prior research
- **Suitability for the New Innovator Award program** – Describe why proposal is “HRHR”
- **Statement of research effort commitment** – State will commit at least 25% research effort toward project
- **Bibliography/citations** – Include critical citations; may be in an abbreviated form as long as identifier is unique
Points to consider:

• Given review process used, be sure that what you write can be easily appreciated by people well outside the field for exceptional innovation and potential for unusually broad impact

• May be helpful to begin with a description of the landscape of the field and current state-of-the-art or boundaries; provide proper context for proposal and why it is so innovative and potentially impactful

• Ease the reader into the jargon of the field

• Though no data or detailed experimental plan are required, convince the reviewer that you have thought deeply about the project – identify risky aspects, how they will be mitigated, alternate approaches

• Also, convince the reviewer that the research will be performed in a robust and rigorous manner – validate new approaches, provide estimates of numbers of human or animal subjects (if used) and why, include that sex will be considered as a biological variable (if appropriate)
NIH Director’s New Innovator Award (DP2)

Gene Carstea, PhD
Scientific Review Officer, New Innovator Award Review
Chief, Cardiovascular and Respiratory Sciences (CVRS) IRG
CSR, NIH

2020-21 Webinar
June 25, 2020
New Innovator Award Review Process

**Receipt**: Late-August

**Two Stage Review Process:**

- **Stage 1**: Mail Review of all Applications
  - Finalists Selection via Prelim Scores

- **Stage 2**: Editorial Panel (meets in March)
  - Discussion of all Finalist Applications
  - Final scores

**Advisory/ Council of Councils**: May

**Selection of Awardees by OD / ICs**

**Public Announcement of Awards**: ~September
Peer-Review Process – Pre-Stage 1

- All applications are assigned to one panel
  - located within the *Cardiovascular and Respiratory Sciences* (CVRS) IRG

- Administrative Review: A check for completeness and ESI eligibility

- Applications are grouped based on areas of science, as identified by applicant

- Potential *Conflicts of Interest* will be considered for each application
  - e.g., Institutional, Collaborative, etc.

- *Mail Reviewers* will be recruited to cover all representative areas of science
Peer-Review Process: Stage 1 (Mail Reviews)

- Recruit Panel of Mail Reviewers
- Match Reviewers with Science
- 3 Reviewers / Application
- Evaluation: 3 Criteria and an Overall Impact Score (1-9)
  1. “Importance and Potential Impact of the Scientific Problem”
  2. “Novelty / Innovativeness of Approach”
  3. “Creative Potential of ESI”

Overall Impact Paragraph
Selection of Finalists for Stage 2

✓ Selection based on Rank Score order by Mail reviewers
  • Overall Impact Scores

✓ Unbiased selection of applications by Editorial reviewers
  • Combination of Scores and Impact statements

In total: Approx. 20% of all submitted applications will advance to Stage 2
Stage 2: Editorial Review

- “Editorial board” consisting of ~25 panelists
  - senior members of the scientific community
  - experts with broad scientific understanding
- Each finalist application is assigned to 3 Editor/Reviewers
  - all finalist applications will be discussed
- Scoring is focused on Impact & Innovation
- Each assigned Editor/Reviewer provides an impact statement and impact score
- Release of final scores and Summary Statements (for all)
  - Discussed statements: will receive 2nd stage impact statements with resume and summary of discussion
  - Non-discussed statements: will receive 1st stage critiques
Questions about the Review process

Contact:

Gene Carstea  SRO, New Innovator Award
Chief, CVRS IRG
301-827-3384; carsteae@csr.nih.gov
This webinar is being recorded.

Q&A Webinar

June 25, 2020 @ 3 PM EDT

Please submit your questions in the “Q&A” box
(scientific inquiries will not be discussed)

Eligibility

https://commonfund.nih.gov/newinnovator
This webinar is being recorded.

Q&A Webinar

June 25, 2020 @ 3 PM EDT

Please submit your questions in the “Q&A” box
(scientific inquiries will not be discussed)

Application & Submission

https://commonfund.nih.gov/newinnovator
Q&A Webinar
June 25, 2020 @ 3 PM EDT

Please submit your questions in the “Q&A” box
(scientific inquiries will not be discussed)

Budget

https://commonfund.nih.gov/newinnovator
This webinar is being recorded.

Q&A Webinar

June 25, 2020 @ 3 PM EDT

Please submit your questions in the “Q&A” box (scientific inquiries will not be discussed)

Review

https://commonfund.nih.gov/newinnovator
This webinar is being recorded.

Q&A Webinar
June 25, 2020 @ 3 PM EDT

Thank you for attending.

A recording of this webinar will be made available on https://commonfund.nih.gov/newinnovator.

If you have additional questions, email us at newinnovator@mail.nih.gov.